News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
kalkine.ca Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
The Neil Gagnon group has reported a 5.8% beneficial ownership stake in Kaltura, Inc., totaling 8,869,949 shares of common stock. This ownership is distributed among Neil Gagnon personally, Gagnon Securities LLC, and Gagnon Advisors, LLC, with specified sole and shared voting and dispositive powers. …
This article provides financial information for OraSure Technologies, Inc. (BX:EP3), specifically focusing on its enterprise value to EBIT forward. The content is presented within the TradingView platform, offering an overview of the company's financial data.
Dimensional Fund Advisors LP reduced its stake in OraSure Technologies by 13.4%, selling 437,763 shares but still holding 2.82 million shares valued at $8.46 million, representing 3.92% of the company. Despite institutional ownership at 93.5%, and a recent insider purchase, analysts maintain a "Reduce" …
Wall Street Zen has upgraded OraSure Technologies (NASDAQ:OSUR) from a "sell" to a "hold" rating, while Weiss Ratings also improved its rating from "sell (e+)" to "sell (d-)". Despite this, analysts collectively rate the stock as "Reduce" with an average price target of $3.00. …
OraSure Technologies (OSUR) recently swung to a quarterly profit with a positive EPS of US$0.09 and increased revenue, driven by new product launches and manufacturing insourcing. Despite these positive indicators like improved GAAP gross margin and operating income, the share price reaction was modest, …
OraSure Technologies Inc. (OSUR) reported its quarterly results for 2026, showing revenue of $30.64M, net income of $6.25M, and diluted EPS of $0.09. This represents a significant improvement compared to the prior year, which saw a net loss of ($19.69M) and an EPS of …
OraSure Technologies, Inc. (OSUR) reported its financial results for the second quarter of 2026. The company announced its performance during this period, which is a key indicator of its operational health and market standing. This update provides investors and stakeholders with crucial insights into …
OraSure Technologies (NASDAQ: OSUR) reported strong Q2 results, exceeding revenue guidance with $30.6 million, driven by increased public-health demand and growth in diagnostic and sample-management products. The company achieved key regulatory milestones, including FDA clearance for its Colli-Pee Dx urine collection kit and Emergency …
OraSure Technologies exceeded its Q2 2026 revenue forecast, reporting $30.6 million against an expected $28.83 million, leading to a 6.92% jump in after-hours trading. The company highlighted improving gross margins, new product clearances like Colli-Pee Dx and OraQuick Ebola 2.0, and a strong balance …
OraSure Technologies reported Q2 2026 net revenue of $30.6 million, a 2% decrease year-over-year, but achieved GAAP profitability with diluted EPS of $0.09, up from a loss of $0.26. This GAAP profit was primarily due to a $22.6 million reduction in acquisition-related contingent consideration, …
OraSure Technologies, Inc. (NASDAQ: OSUR) reported total revenue of $115.02 million USD last year. The Human Immunodeficiency Virus segment was its top performer, generating $49.80 million USD, though this was a decrease from $60.80 million USD in the prior year. The United States was …
Private Management Group, Inc., an investment adviser, has disclosed a 5.5% beneficial ownership stake in OraSure Technologies Inc. (OSUR) common stock, totaling 3,797,682 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are managed across …
OraSure Technologies Inc (OSUR) currently holds a financial score of 6.97, placing it 116th out of 199 companies in the Healthcare Equipment & Supplies industry. While its financial status is deemed robust, its operational efficiency is low. The company recently reported a quarterly revenue …
This article provides a risk assessment for OraSure Technologies Inc (OSUR), detailing its current risk score, industry ranking, and beta value. It includes various financial metrics such as volatility, maximum drawdown, Sharpe Ratio, and liquidity indicators. The report also notes the neutral impact of …
OraSure Technologies (NASDAQ:OSUR) is scheduled to release its Q2 2026 earnings after market close on Wednesday, August 5th. Analysts anticipate a loss of $0.27 per share on revenue of $28.85 million. Despite a consensus "Reduce" rating and an average price target of $3.00, the …
This article provides a detailed income statement for OraSure Technologies Inc (OSUR), offering quarterly and annual financial performance data. It includes key metrics such as total revenue, cost of revenue, operating expenses, and net income, allowing users to analyze the company's operational efficiency and …
This article details the major shareholders and institutional holdings of OraSure Technologies Inc (OSUR), including top individual institutional investors and types of shareholder entities. It provides a breakdown of institutional shareholding over recent quarters, displaying the number of institutions, shares held, proportion, and changes. …
This article provides a detailed company profile of OraSure Technologies Inc (OSUR), including its background, business scope, and financial data. It highlights the company's focus on decentralizing diagnostics with rapid diagnostic tests and sample collection devices, and lists key executives, institutional shareholdings, and top …
This article provides a detailed financial overview of OraSure Technologies Inc (OSUR), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, and margins across various quarters and fiscal years. The report indicates …
This article provides a detailed quarterly and annual cash flow statement for OraSure Technologies Inc (OSUR), covering operating, investing, and financing activities. It presents extensive financial data including net income, capital expenditures, and free cash flow, alongside explanations of what each cash flow type …
This article provides a detailed revenue breakdown for OraSure Technologies Inc (OSUR), categorizing its income by business segments and geographical regions. It highlights that HIV products account for the largest proportion of net product and services revenues, and the United States is the primary …
OraSure Technologies, Inc. (LSX:881351) generated 97.93 million EUR in revenue last year, with its Human Immunodeficiency Virus segment contributing the most at 42.40 million EUR. The United States was the largest regional contributor, accounting for 66.63 million EUR of the company's revenue.
This article identifies three promising penny stocks—OraSure Technologies (OSUR), Castellum (CTM), and Protalix BioTherapeutics (PLX)—each with market caps over $60M. It highlights their financial health, recent achievements, and growth prospects, noting that while some are currently unprofitable, they exhibit strong balance sheets and strategic …
The article provides a financial metric, "Enterprise value to revenue forward," for OraSure Technologies, Inc. (NASDAQ: OSUR). It appears to be a stub or a data point from a financial platform like TradingView, indicating no specific value or further details beyond the title of …
OraSure Technologies, Inc. is scheduled to release its Q2 2026 financial results on August 5, 2026, after the market closes. This will be followed by a quarterly conference call at 5 p.m. ET, which interested investors can access via a webcast on the company’s …
OraSure Technologies (NASDAQ: OSUR) will release its second-quarter 2026 financial results on August 5, 2026, after the market closes, followed by a conference call at 5:00 p.m. ET. Investors can access a live webcast of the call on the company's investor relations website, with …
Search by ticker symbol or company name and select a result to open its chart.